FINASTERIDE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Global Finasteride Market Size and Forecast – 2026 To 2033

The global finasteride market is expected to grow from USD 150.0 Mn in 2026 to USD 194.5 Mn by 2033, registering a compound annual growth rate (CAGR) of 3.8% from 2026 to 2033. The market for global finasteride is poised for significant expansion, fueled by the rising burden of benign prostatic hyperplasia (BPH) among aging male populations, which sustains demand for finasteride-based therapies.

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in its latest Urologic Diseases in America data updated in 2025, reported that Benign Prostatic Hyperplasia / Lower Urinary Tract Symptoms affected 29%–35% of U.S. men aged 65 years and older annually between 2012 and 2021. This substantial prevalence among older men reinforces the underlying treatment population for BPH therapies.

Key Takeaways of the Global Finasteride Market

• 1 mg is projected to hold 57.8% of the global finasteride market share in 2026, making it dominant product type segment, across North America due to established androgenetic alopecia treatment pathways. The U.S. FDA’s approved labeling for Propecia (finasteride 1 mg) recognizes its use for the treatment of male pattern hair loss, supporting the established regulatory position of the 1 mg segment.
• Benign Prostatic Hyperplasia (BPH) is projected to hold 61.7% of the global finasteride market share in 2026, making it dominant indication segment, with Europe representing an important market due to the established use of 5 mg finasteride for BPH. The European Medicines Agency confirms that finasteride 5 mg has been authorized in the EU since 1992 for the symptomatic treatment of BPH, reinforcing its long-standing regulatory and clinical role in the region.
• Tablet is projected to hold 95.2% of the global finasteride market share in 2026, making it dominant formulation segment, across Asia Pacific supported by established regulatory availability of oral finasteride products. For instance, Japan’s PMDA lists approved finasteride 1 mg tablets for androgenetic alopecia, with multiple products having been marketed since 2016–2017, demonstrating the established availability of oral tablet formulations in the region.
• North America market maintains dominance with an expected share of 37.8% in 2026, bolstered by established access to finasteride across urology and dermatology care and continued availability of generic oral products. For instance, Health Canada issued a 2025 Notice of Compliance for 1 mg finasteride tablets, confirming continued regulatory availability of oral finasteride for the Canadian market.
• Asia Pacific is expected to exhibit the fastest growth in the global finasteride market, registering an estimated CAGR of 4.9% during 2026–2033, driven by expanding access to pharmacological treatment for male pattern hair loss and BPH. For instance, Australia’s TGA maintains active registrations for both Propecia 1 mg and Proscar 5 mg finasteride tablets, demonstrating established regulatory access to both major oral strengths in the region.

Segmental Insights 

To learn more about this report, Request Free Sample

Why Do 1 mg Dominate the Global Finasteride Market?

1 mg is projected to hold the market share of 57.8% in 2026, as a result of the existing established use of the agent in androgenetic alopecia, the high awareness on the part of the physicians and the availability of multiple oral dosage forms. Its mechanism of action in lowering DHT coupled with simple, single daily oral therapy and generic availability makes it highly adoptable among men. For instance, in September 2025, Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) specifically confirms oral 1 mg finasteride as an approved treatment for AGA, while the 5 mg formulation is designated for BPH, reinforcing the distinct clinical positioning of the 1 mg segment.

Why Does Benign Prostatic Hyperplasia (BPH) Represent the Largest Indication Segment in the Finasteride Market? 

To learn more about this report, Request Free Sample

Benign Prostatic Hyperplasia (BPH) is projected to hold a market share of 61.7% in 2026, attributed to the increasing prevalence of enlarged prostate glands in aged men and to finasteride's documented effectiveness in both shrinking the prostate and minimizing its disease process. It has a favorable efficacy and safety profile to warrant continued long-term use as well as its proven effectiveness in preventing acute urinary retention and surgery due to BPH. For instance, the European Association of Urology (EAU) guidelines 2026 suggest 5-reductase inhibitors (e.g., finasteride) for men with moderate-to severe lower urinary tract symptoms, with a high chance of deterioration in 5-reductase inhibitor candidate. Especially for patients with a prostate volume greater than 40 ml, 5-reductase inhibitors are advised to treat such lower urinary tract symptoms.

Tablet Segment Dominates the Global Finasteride Market

The tablet segment is projected to hold a market share of 95.2% in 2026, since it offers precise dosage, ease of use, proven track-record in the clinics and availability in both 1 mg and 5 mg dosages. These factors coupled with a history of regulatory approval in oral finasteride and availability of generic drugs make the prescription of tablet form extremely widespread among hair loss patients and in cases of BPH. For instance, in March 2024, Finasteride 1 mg film-coated tablets were given marketing authorization from Irish Health Products Regulatory Authority (HPRA) for use in the prevention of early androgenetic alopecia in males 18 to 41 years old, indicating ongoing regulatory endorsement of this oral dosage form.

Current Events and their Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Finasteride Market Dynamics

To learn more about this report, Request Free Sample

Market Drivers

Rising prevalence of benign prostatic hyperplasia among aging male populations

The increasing prevalence of benign prostatic hyperplasia (BPH) among older men continues to expand the patient population requiring long-term pharmacological management, supporting demand for finasteride 5 mg therapies. For instance, the UK government’s NHS information service reports that benign prostate enlargement may affect up to 25% of men by age 65, with prevalence increasing as men age. This age-associated disease burden supports sustained demand for BPH treatments such as finasteride.

Increasing awareness and diagnosis of male pattern hair loss

Increasing awareness and diagnosis of male pattern hair loss are encouraging more men to seek medical evaluation and pharmacological treatment, supporting demand for finasteride. For instance, in February 2025, U.S. study using the NIH All of Us dataset found that male androgenetic alopecia reporting was concentrated among younger age groups, with 29.37% of reported male androgenetic alopecia cases occurring among men aged 30–39 years. Finasteride was the predominant prescription treatment, used in 38.9%–60.7% of male androgenetic alopecia patients across age groups.

Wider availability of generic finasteride

The increasing availability of generic finasteride is supporting market growth by improving affordability and ensuring broader access to established oral therapies for BPH and male pattern hair loss. For instance, the U.S. FDA’s current labeling database lists more than 30 finasteride oral tablet products under ANDAs, with multiple generic products receiving updated labeling during 2026, including products from Ascend Laboratories, Preferred Pharmaceuticals, RemedyRepack, and Teva. This broad generic supply is strengthening product availability and supporting continued use of low-cost oral finasteride.

Emerging Trends

Growing adoption of topical finasteride formulations

Topical finasteride is emerging as a differentiated alternative to conventional oral tablets, particularly in androgenetic alopecia treatment. Recent regulatory approvals and ongoing formulation development are expanding the market for localized delivery approaches.

Expansion of telemedicine-enabled finasteride treatment

Digital dermatology and telemedicine platforms are increasingly supporting remote consultation, prescription management, treatment follow-up, and adherence monitoring for hair-loss patients. This trend is improving access to finasteride therapy while supporting more convenient, digitally managed treatment pathways.

Integration of AI and digital tools in hair-loss management

AI-assisted scalp imaging, trichoscopy, and quantitative hair-density assessment are gaining attention for improving diagnosis and monitoring treatment response. These technologies could enable more personalized finasteride treatment decisions and objective evaluation of therapeutic outcomes.

Regional Insights

To learn more about this report, Request Free Sample

Why is North America a Strong Market for Finasteride?

North America leads the global finasteride market, accounting for an estimated 37.8% share in 2026, due to the presence of a highly advanced and established pharmaceutical industry, a robust spending on healthcare services and adequate regulatory systems. Easy availability of products along with rapid entry into market channels are facilitated by conducive policies related to intellectual property rights and speedy drugs- approval process.

For instance, the U.S. Food and Drug Administration (FDA)’s Abbreviated New Drug Application (ANDA) framework enable generic producers to demonstrate bioequivalence rather than conduct duplicate human clinical trials while the Hatch-Waxman context provides means for contesting patent validity and awarding a 180-day generic exclusivity. The market is further supported by high network of healthcare sector and high awareness levels of hair loss treatment and BPH remedies.

Why Does Asia Pacific Finasteride Market Exhibit High Growth?

Asia Pacific is expected to exhibit the fastest growth in the global finasteride market, registering an estimated CAGR of 4.9% during 2026–2033. The region is projected to account for 31.2% of the global market in 2026, owing to improved access to healthcare along with the rising awareness and significance of the issue, i.e., male pattern baldness and prostate health and the increased availability of pharmaceuticals through various distribution channels. Favorable government policies aimed at improving access to healthcare, alongside rapid growth of e-pharmacy services has led to the development and delivery of prescription medicines across the region.

For instance, India’s Ministry of Health and Family Welfare launched the ABDM Drug Registry in June 2026, covering more than 123,000 branded and 10,000 generic medicines and enabling integration with e-prescription platforms and digital healthcare applications. (Source: Press Information Bureau) Furthermore, the rise in e-health adoption rates and increased availability of low-cost medicines contribute in penetration of the market at an optimal level across the emerging economies.

Global Finasteride Market Outlook for Key Countries

Why is the U.S. Leading Innovation and Adoption in the Finasteride Market?

The U.S is at the forefront of innovation and adoption due to existing and continually emerging digital oral finasteride treatment models. The country has also witnessed innovation and exploration of topical and combination finasteride via telemedicine channels, which is paving a new way of access and product differentiation. This is leveraging the first mover advantage provided by the existing oral therapies for further growth and innovation in the treatment domain.

Is Japan a Favorable Market for Finasteride Market?

Finasteride market is strong in Japan where a traditional usage has been developed in treatment of male pattern hair loss. This market is also expected to penetrate the oral generic application and increase the local registration of finasteride products. The comprehensive distribution network for dermatology products and pharmaceutical industry is providing a support system for using the finasteride therapy to obtain the benefits of each market conditions.

Is China Emerging as a Key Growth Hub for the Finasteride Market?

China represents a growing market for finasteride, especially for male patterned baldness, next-generation topical finasterides. It is developing more alternative markets based on oral treatment: topical combinations and more differentiated therapies. China's developing specialized dermatology and rising interest in alternative formats of finasteride are likely to further solidify its place in future growth.

Why Does Germany Top the European Finasteride Market?

The urology & dermatology ecosystem for prescription treatment and widespread access to prescription products with high utilization of generic finasteride are Germany’s defining characteristics across the European market. Demand derives from both existing BPH treatment and established male pattern baldness management in a country where the mature pharmacy & healthcare infrastructure ensures routine access to oral products. The increasingly common use of the digital pathway for hair loss consultation and subsequent prescription also opens an additional avenue of treatment access.

Is Finasteride Market Developing in India?

India has established a key market for finasteride across male pattern hair loss and potential topical applications, transitioning from a traditional oral market towards both topical and combination treatments for finasteride. This opens up significant opportunities for innovative and differentiated products to expand its use. Increasing manufacturing facilities of pharmaceutical drugs and expansion of dermatology treatments, among others are strong market drivers.

Finasteride Market by Route of Administration and Formulation

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

How is the development of topical finasteride formulations with localized administration creating new growth opportunities in the finasteride market?

Finasteride market will have promising opportunities in topical formulations that can offer local delivery of finasteride to treat androgenetic alopecia without increasing potential systemic absorption related with oral treatment. Spray based and other targeted deliveries of the formulations would permit unique product characteristics as patients look for alternatives for oral therapy. For instance, in August 2025, Singapore’s Health Sciences Authority (HAS) approved the topical finasteride spray, FINJUVE (2.275 mg/mL), for the use of men (18–41 years old) who have mild to moderate androgenetic alopecia, demonstrating increasing regulatory acceptance of topical finasteride products.

Market Players, Key Development, and Competitive Intelligence

To learn more about this report, Request Free Sample

Key Developments

• In July 2026, Rxilient Medical entered into a partnership with Polichem, an Almirall subsidiary, securing exclusive commercialization rights for Finjuve (topical finasteride) in Singapore, Malaysia, the Philippines, Thailand, and Indonesia. Finjuve is a topical finasteride spray for androgenetic alopecia and had already received approval in Singapore and Malaysia in 2025.
• In June 2026, Dayspring Pharma announced positive topline Phase II results for CG2001, a topical combination of 5% minoxidil and finasteride, in men with androgenetic alopecia. The trial met its primary endpoint, with the 0.075% finasteride twice-daily formulation demonstrating a statistically significant improvement in target-area hair count versus placebo at Week 24. The company is now engaging with regulatory authorities to determine the next phase of clinical development.
• In May 2026, Triple Hair Group Inc. announced the launch of a 500-patient Phase III clinical trial in India for TH07, a topical triple-combination therapy containing finasteride, minoxidil, and latanoprost for male androgenic alopecia. The Indian study forms part of the company’s coordinated international Phase III program, which is expected to evaluate TH07 in approximately 920 male patients across India and Canada.
• In December 2024, Apotex Inc. through its specialty pharma division Searchlight, entered into an exclusive agreement with Almirall to market and distribute FINJUVE (finasteride) topical spray in Canada, subject to regulatory approval. FINJUVE is a 0.25% topical finasteride spray intended for the treatment of androgenetic alopecia in adult patients. The agreement gives Apotex Canadian commercialization rights for FINJUVE and expands its branded dermatology portfolio.

Competitive Landscape

The global finasteride market is moderately competitive, with competition centered on formulation innovation, product affordability, regulatory compliance, treatment accessibility, and differentiation between oral and topical therapies. Market participants are increasingly focusing on topical finasteride development, expansion of generic oral products, digital prescribing channels, and safety-focused treatment management across androgenetic alopecia and benign prostatic hyperplasia. Key focus areas include:

• Development of topical and localized finasteride formulations
• Expansion of cost-effective generic 1 mg and 5 mg oral products
• Integration of telemedicine and digital prescribing platforms for hair-loss treatment
• Advancement of combination therapies for androgenetic alopecia
• Strengthening of pharmacovigilance, patient safety, and treatment-monitoring capabilities

Market Report Scope 

Analyst Opinion (Expert Opinion)

• In the coming years, global finasteride market will increasingly shift from conventional oral tablets toward more differentiated, patient-centric treatment options, particularly topical formulations for androgenetic alopecia. We expect continued development of localized delivery systems, combination therapies, and digitally enabled treatment pathways, while oral 1 mg and 5 mg products remain the commercial foundation of the market.
• The maximum opportunities are foreseen within topical finasteride for male pattern baldness/androgenetic alopecia in India. India combines a large addressable male population, increasing awareness of hair-loss treatment, expanding dermatology access, and growing acceptance of digitally enabled healthcare, creating an attractive environment for affordable topical finasteride and combination products.
• In order to gain a competitive advantage market players should prioritize topical formulation innovation, optimized dosing, and combination therapies while maintaining competitive pricing for established oral products. Differentiation should also focus on patient convenience, safety-oriented product positioning, digital consultation and prescription channels, and strong physician engagement to improve treatment initiation and long-term adherence.

Market Segmentation

• Product Type Insights (Revenue, USD Mn, 2021 - 2033)
  • 1 mg
  • 5 mg
  • Topical Finasteride
• Indication Insights (Revenue, USD Mn, 2021 - 2033)
  • Benign Prostatic Hyperplasia (BPH)
  • Male Pattern Baldness / Androgenetic Alopecia
• Formulation Insights (Revenue, USD Mn, 2021 - 2033)
  • Tablet
  • Topical Solution
  • Topical Foam
• End User Insights (Revenue, USD Mn, 2021 - 2033)
  • Dermatology Clinics
  • Urology Clinics
  • Hospitals
  • Home Care
  • Others
• Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Mn, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa

Sources

Primary Research Interviews

• Dermatologists and hair-loss specialists involved in androgenetic alopecia diagnosis and finasteride treatment
• Urologists and urology specialists managing benign prostatic hyperplasia (BPH) with finasteride
• Trichologists and hair-restoration specialists evaluating male pattern hair loss and treatment outcomes
• Clinical pharmacists and prescribing physicians involved in finasteride therapy and patient counseling
• Researchers and formulation specialists developing topical and combination finasteride therapies

Stakeholders

• Branded and generic finasteride manufacturers
• Topical finasteride and dermatology-product developers
• Pharmaceutical contract manufacturers and formulation-development companies
• Dermatology and urology clinics
• Hospitals and specialty healthcare centers
• Retail, hospital, and online pharmacies
• Telemedicine and digital hair-loss treatment platforms
• Pharmaceutical distributors and healthcare wholesalers
• End-use Sectors
  • Dermatology Clinics
  • Urology Clinics
  • Hospitals and Health Systems
  • Hair Restoration and Specialty Clinics
  • Retail and Community Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies and Digital Healthcare Platforms
  • Home-Based and Telemedicine Care
• Regulatory & Health Bodies
  • U.S. Food and Drug Administration (FDA) – Finasteride drug approvals, labeling, safety information, and regulatory status
  • European Medicines Agency (EMA) – Finasteride safety assessments and European regulatory information
  • Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom – Finasteride safety warnings and pharmacovigilance
  • Pharmaceuticals and Medical Devices Agency (PMDA), Japan – Finasteride product approvals and regulatory information
  • National Medical Products Administration (NMPA), China – Finasteride drug registration and regulatory information

Databases

• ClinicalTrials.gov – Finasteride clinical trials and studies for androgenetic alopecia and BPH
• WHO International Clinical Trials Registry Platform (ICTRP) – Global clinical-trial information
• FDA Drugs@FDA / Orange Book – Finasteride approvals, applications, and regulatory information
• FDA FAERS – Adverse-event and post-marketing safety information for finasteride
• DailyMed – Current U.S. finasteride prescribing information and labeling
• WHO Global Health Observatory (GHO) – Population and health-related epidemiological data

Associations

• American Academy of Dermatology (AAD)
• American Urological Association (AUA)
• European Academy of Dermatology and Venereology (EADV)
• European Association of Urology (EAU)
• International Society of Hair Restoration Surgery (ISHRS)
• International Society of Dermatology (ISD)
• European Hair Research Society (EHRS)

Public Domain Sources

• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) – BPH and prostate-health information
• National Institutes of Health (NIH) – Clinical and biomedical research information
• Centers for Disease Control and Prevention (CDC) – Population and demographic health data
• U.S. Census Bureau – Aging male population and demographic statistics
• World Health Organization (WHO) – Global health and demographic data
• National health ministries and statistical agencies – Country-level population, healthcare, and disease-burden information
• Government drug formularies and public regulatory databases – Finasteride product availability, approvals, and prescribing information

Proprietary Elements:

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 10 years.